OliX Pharmaceuticals, Inc.

As of June 30, 2026, OliX Pharmaceuticals, Inc. carries a market capitalization of 3.16T, placing it among publicly traded companies globally. Its enterprise value stands at 2.97T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, OliX Pharmaceuticals, Inc. has 20.30M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 241.62, and the price-to-book ratio stands at 13.40.

These figures are as of June 30, 2026. The EV/Sales ratio of 217.60 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.97T versus a market cap of 3.16T, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, OliX Pharmaceuticals, Inc. maintains a current ratio of 11.74, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.77, indicating elevated leverage, while an interest coverage ratio of -35.26 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, OliX Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -10.86, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.01, reflecting losses generated across the asset base. The company generates approximately 183.65M in revenue per employee across its workforce of 74.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, OliX Pharmaceuticals, Inc. recorded 128.02M in income tax expense. The company reported a pretax loss of -13.90B and -14.03B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, OliX Pharmaceuticals, Inc.'s stock has gained approximately 5.84% over the past 52 weeks. The 50-day moving average sits at 105,832.00, while the 200-day moving average is 139,542.50.

Over the twelve months ended June 30, 2026, OliX Pharmaceuticals, Inc. generated 13.64B in revenue and converted that into -14.03B in net income, yielding earnings per share of -662.61. EBITDA reached -39.21B, while operating income came in at -41.55B.

As of June 30, 2026, OliX Pharmaceuticals, Inc. holds 214.15B in cash and equivalents against 20.82B in total debt, resulting in a net debt position of -91.84B. Total book value stands at 235.69B, with working capital of 200.87B providing operational flexibility.

OliX Pharmaceuticals, Inc. produced -30.08B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.23B in capital expenditures, free cash flow totaled -32.31B - equivalent to -1,526.12 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -304.72 and net profit margin of -102.89 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.98: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.84, meaning OliX Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

OliX Pharmaceuticals, Inc.'s most recent stock split took place on December 3, 2020 with a 1:2 split ratio.

As of June 30, 2026, OliX Pharmaceuticals, Inc. has an Altman Z-Score of 51.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.